Genetic factors, including SNPs in ZNF423 and cathepsin O (CTSO), influence susceptibility to ERα + breast cancer and response to SERM therapy, highlighting the potential for personalized medicine [171–173]. The gene discussed is CTSO; the disease is breast cancer.